Hepatitis B virus genotype is an independent prognostic factor of telbivudine and tenofovir treatment in hepatitis B surface antigen‐positive pregnant women
Authors:
Open Access
- 29 November 2021
- journal article
- research article
- Published by Wiley in Food Science & Nutrition
- Vol. 10 (1) , 3-11
Abstract
To investigate whether HBV genotype influences the effect of tenofovir and telbivudine on HBV DNA and RNA levels in HBsAg‐positive pregnant women. This was a retrospective study of 74 HBsAg‐positive pregnant women in Guizhou of China. All patients were treated with telbivudine or tenofovir from 12 weeks of pregnancy and HBV infection to the date of delivery. Blood samples were collected at 12–24, 28–32, and 36–40 weeks of pregnancy for the measurement of genotype, HBsAg, hepatitis B e antigen (HBeAg), HBV DNA, HBV RNA, and liver function, including alanine transaminase, aspartate transaminase, total bilirubin, total bile acids, cholinesterase, alkaline phosphatase (ALP), and gamma‐glutamyl transferase. All women with HBsAg were followed up. The HBV genotype was B in 64.9% and C in 35.1%. There were 37 patients of telbivudine and tenofovir group respectively. The telbivudine and tenofovir groups showed no differences in demographic and clinical characteristics, including liver function tests, HBsAg, HBeAg, log10(HBV DNA), and log10(HBV RNA). Compared with baseline (12–24 weeks), telbivudine group showed a significant increase in ALP and significant reductions in HBsAg, HBeAg, log10(HBV DNA), and log10(HBV RNA) at 36–40 weeks (p < .05). Tenofovir group exhibited a significant increase in ALP and significant reductions in HBeAg, log10(HBV DNA), and log10(HBV RNA) at 36–40 weeks, compared with baseline (p < .05). HBV genotype (B vs. C) was independently associated with HBV DNA change after therapy (p = .005). In telbivudine group, log10 (HBV DNA) increased from 3.38 (2.00–7.30) to 7.43 (4.68–8.70). In tenofovir group, log10 (HBV DNA) decreased from 7.52 (3.32–8.70) to 2.98 (2.00–5.01). HBV genotype was independently associated with HBV DNA change response to telbivudine or tenofovir in pregnant women with hepatitis B. These findings might be helpful for risk assessment regarding vertical transmission of HBV in HBeAg‐positive mothers treated with nucleos(t)ide analogues.Keywords
Funding Information
- National Natural Science Foundation of China (82060114, 32060034, 81760116)
This publication has 40 references indexed in Scilit:
- Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virusJournal of Hepatology, 2014
- Kinetics and Prediction of HBsAg Loss during Long-Term Therapy with Nucleos(t)ide Analogues of Different Potency in Patients with Chronic Hepatitis BPLOS ONE, 2014
- Chronic HBV infection among pregnant women and their infants in Shenyang, ChinaVirology Journal, 2013
- PD-1 expression on CTL may be related to more severe liver damage in CHB patients with HBV genotype C than in those with genotype B infectionJournal of Viral Hepatitis, 2012
- Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dogJournal of Gastroenterology, 2012
- Telbivudine Prevents Vertical Transmission From HBeAg-Positive Women With Chronic Hepatitis BClinical Gastroenterology and Hepatology, 2012
- A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infectionJournal of Hepatology, 2011
- Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg LossThe Journal of Infectious Diseases, 2011
- The clinical implications of hepatitis B virus genotype: Recent advancesJournal of Gastroenterology and Hepatology, 2011
- Real-Time PCR in Clinical Microbiology: Applications for Routine Laboratory TestingClinical Microbiology Reviews, 2006